Business Wire

STARMUS V, Host of The Stephen Hawking Medal, Hosts a Special Evening in Davos at WEF with Jean-Michel Jarre, Brian May and Luminary Scientific Panel

Share

This year, WEF was treated to a rare panel discussion bridging the fields of astronomy and music. Global CEOs and international media had the opportunity to hear from Dr. Brian May, Jean-Michel Jarre and Dr. Garik Israelian discuss STARMUS and the special connection between science and music. Flanked by a panel of renowned scientists, astronauts, and Nobel laureates, Jean-Michel Jarre introduced his groundbreaking tribute to the Apollo Missions for their 50th Anniversary.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005171/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WEF panel for STARMUS, Michel Mayor, Jean-Michel Jarre, Garik Israelian, and moderator Marco Larsen engage with the Davos audience. Photo by: Andres Eggenberger

The esteemed panel included Swiss Astronaut Claude Nicollier, Garik Israelian, Brian May, and Michel Mayor. (Special thanks to the support from Kaspersky Labs and to the Stephen Hawking Medal for Science Communication sponsor, Omega.)

The event drew many of the world’s CEOs and music fans in Davos for The World Economic Forum eager to hear about the new musical tribute to the 50 Year Anniversary of Apollo Missions by Jean-Michel Jarre.

“For the first time, the use of ‘star sounds’ library developed by Dr. Garik Israelian will be incorporated into composed music. While it’s a relatively unknown phenomenon, it is no doubt real. I’m excited to include the actual sounds of planets and stars in this groundbreaking ode to the Apollo Missions.” - Jean-Michel Jarre.

ABOUT STARMUS V:

Fans from around the globe will descend on Zurich, Switzerland from June 24-29, 2019, to celebrate STARMUS V - the world’s most notable science and art festival. This year promises to be the most important program to date, coinciding with the 50th anniversary of the moon landings, one of science’s most important milestones. STARMUS V will also host a special ceremony announcing the 2019 Stephen Hawking Medal for Science Communication winners, supported by Omega and Kaspersky Labs.

Jean-Michel Jarre will headline a concert with “star sounds” never before heard here on earth. In addition to astronaut Michael Collins joining as the keynote, STARMUS V will host a remarkable line-up of presenters hand-selected by the STARMUS board (Stephen Hawking posthumous, May-Brit Moser, Elizabeth Blackburn, Linda Buck, Brian May, Peter Gabriel, Richard Dawkins, Alexei Leonov, Jill Tarter, Robert Williams, David Eicher, Emmanuelle Charpentier and founder, Garik Israelian). The 2019 festival STARMUS V will also feature seven of the original Apollo Mission crew, science legend and champion Bill Nye along with rock stars Brian May, Brian Eno, Steve Vai, and Rick Wakeman.

And as a special homage to the Apollo Missions and those who made them possible, Hans Zimmer will be performing a very special concert “Once Upon a Time on The Moon.”

According to Garik Israelian, STARMUS founder, the 2019 festival has been designed to ask tough questions about our place in the universe at a pivotal point in human history: “The importance of STARMUS V cannot be understated. At a time when the world retreats to isolationism, collaboration is needed to strategically present the ideas, evidence, and challenges we collectively face – and uniquely confront. We believe the biggest and best achievements of the human race are a result of that scientific collaboration.”

STARMUS V will welcome 12 Nobel laureates to the stage, as well as luminaries from the worlds of art and music, for six days of discussion, debate, and engagement across the sciences, from microbiology and biochemistry to astrophysics and neuroscience. The 2019 programme will bring together some of the most intelligent, creative, and artistic people on the planet.

Other speakers include Sir Martin Rees, Brian Cox, Emmanuelle Charpentier, and Helen Sharman.

Tickets are now officially on sale and can be purchased at www.starmus.com.

STARMUS V HONORED PARTNERS

OMEGA and The Stephen Hawking Medal:

OMEGA is a prestigious Swiss watchmaker and member of the Swatch Group Ltd. Since 1848, the brand has been synonymous with excellence, innovation, and precision, as well as a pioneering spirit, demonstrated by its achievements in sports timekeeping, the oceans, and space. In fact, since 1965, the OMEGA Speedmaster has been worn on each of NASA's manned missions including all six moon landings.

Kaspersky Lab:

Kaspersky Lab is a global cybersecurity company, which has been operating in the market for 21 years. Kaspersky Lab’s deep threat intelligence and security expertise are constantly transforming into next-generation security solutions and services to protect businesses, critical infrastructure, governments and consumers around the globe. The company’s comprehensive security portfolio includes leading endpoint protection and a number of specialized security solutions and services to fight sophisticated and evolving digital threats. Over 400 million users are protected by Kaspersky Lab technologies and we help 270,000 corporate clients protect what matters most to them. Learn more at www.kaspersky.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PUBLIC, NYC
Marco Larsen
Marco@publicnewyorkcity.com
646-812-4444

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists23.4.2024 14:00:00 EEST | Press release

Incyte (Nasdaq:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423725958/en/ “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to our portfolio. This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “EP262 and EP547 are complementary additions to our portfolio, prov

REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements23.4.2024 13:43:00 EEST | Press release

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share. The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024). 2023 Financial Statement The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022. Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022). EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022). The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million. The Shareholders’ Meeting also adopted the following reso

Eaton’s Mobility Group Chosen to Supply Electromechanical Variable Valve Actuation Technology to Great Wall Motor23.4.2024 13:30:00 EEST | Press release

Intelligent power management company Eaton today announced it has been chosen to supply an electromechanical actuation system (EMAS) that can deliver an early intake valve closing (EIVC) to the China-based automaker Great Wall for use in a line of hybrid-electric vehicles (HEV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423118914/en/ Eaton’s electromechanical actuation system (EMAS) can be easily integrated into a valvetrain and the cylinder head space and controlled by a simple electric actuator. (Photo: Business Wire) “Emissions regulations are driving the adoption of new technologies by our global customers,” said Alessio Lorenzon, global engineering manager, Valves, Eaton’s Mobility Group. “We’re proud to supply Great Wall with our variable valve actuation technology which, in combination with vehicle hybridization, will improve fuel economy in their newest hybrid passenger vehicle lineup.” The Eaton EMAS is a di

Rasa Recognized as a Representative Vendor in Gartner® Market Guide for Conversational AI Solutions23.4.2024 13:03:00 EEST | Press release

Rasa, a leader in generative conversational AI, proudly announces its recognition as a Representative Vendor in the Gartner® Market Guide for Conversational AI Solutions. Rasa believes this acknowledgment highlights its pivotal role in the future of AI-driven communication and its commitment to delivering innovative solutions that enhance business interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423570629/en/ Rasa has been recognized as a Representative Vendor in the Gartner Market Guide for Conversational AI Solutions, highlighting its role in transforming business operations through AI-driven conversations. This acknowledgment underscores the importance of evaluating the Conversational AI market to enhance customer interactions, achieve cost efficiencies, and elevate customer service. (Graphic: Business Wire) Melissa Gordon, CEO of Rasa, shares her thoughts: “We think recognition from Gartner® validates our

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer23.4.2024 13:00:00 EEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye